Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

How to decide on the optimal duration of anticoagulatn therapy in carriers of the factor V Leiden mutation.

Thrombosis and haemostasis - 1 Nov 2000

Middeldorp S, Büller H R

Abstract excerpt

No abstract is available from the source.

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Anticoagulants
Share to Decision Making
Share to Factor V
Share to Heterozygote

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Mutation

Source

Identifiers

PMID: 11127847

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

How to decide on the optimal duration of anticoagulatn therapy in carriers of the factor V Leiden mutation.PMID 11127847Read ↗

Role of thrombophilia in deciding on the duration of anticoagulation.Semantic proximity Read ↗

Making anticoagulation safer.Semantic proximity Read ↗

Factor V Leiden, prothrombin G20210A substitution and hormone therapy: indications for molecular screening.Semantic proximity Read ↗

Management of concomitant factor VII deficiency and Factor V Leiden mutation.Semantic proximity Read ↗

Anticoagulation duration in heterozygous factor V Leiden: a decision analysis.Semantic proximity Read ↗

North American Thrombosis Forum, AF Action Initiative Consensus Document.Semantic proximity Read ↗

Bleeding with anticoagulation therapy - who is at risk, and how best to identify such patients.Semantic proximity Read ↗

Is a genotype-guided therapy the optimal strategy to personalize anti-thrombotic management in patients with acute coronary syndrome?Semantic proximity Read ↗

Age-stratified outcome of a genotype-guided dosing algorithm for acenocoumarol and phenprocoumon.Semantic proximity Read ↗

Genotype-guided versus standard vitamin K antagonist dosing algorithms in patients initiating anticoagulation. A systematic review and meta-analysis.Semantic proximity Read ↗

Current challenges in personalizing warfarin therapy.Semantic proximity Read ↗

Extending half-life in coagulation factors: where do we stand?Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.